COMMENTARY: Review: Anti-tumor necrosis factor antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy

Shoor, Stanford
November 2006
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p65
Academic Journal
The article presents the author's comments on a medical study on anti-tumor necrosis factor (anti-TNF) antibody therapy for rheumatoid arthritis. The study revealed that the antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy. But the author says that study patients and coexistence of an already altered host immune system have made it difficult to prove such occurrences and to ascribe them to the treatment or the underlying disease.


Related Articles

  • Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Young Lee; Jin Woo; Young Rho; Seong Choi; Jong Ji; Gwan Song // Rheumatology International;Apr2008, Vol. 28 Issue 6, p553 

    This present study was designed to examine (1) whether a combination therapy of TNF (tumor necrosis factor) blockers and methotrexate (MTX) is better than MTX monotherapy, and (2) if the TNF inhibitors such as etanercept, infliximab and adalimumab are all same for treating patients with active...

  • Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Burska, Agata N.; Sakthiswary, Rajalingham; Sattar, Naveed // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Objective: Beyond the joints, TNFi (tumour necrosis factor inhibitor) therapy may confer systemic benefits in rheumatoid arthritis (RA). Several studies have investigated the role of TNFi on insulin resistance/sensitivity (IR/IS). This question is of general interest given the emerging evidence...

  • Tubulointerstitielle-Nephritis-mit-Uveitis (TINU)-Syndrom. Häusler, U.; Guminski, B.; Helmchen, U.; Kisters, K.; Heinz, C.; Braun, J. // Zeitschrift für Rheumatologie;May2013, Vol. 72 Issue 4, p393 

    The tubulo-interstitial nephritis and uveitis (TINU) syndrome, first described in 1975, is a rare disease most probably of autoimmune origin that is characterized by unilateral or bilateral uveitis and tubulointerstitial nephritis. Most patients are adolescents and it is sometimes associated...

  • Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-α therapy. Erer, Burak; Yilmaz, Gulsen; Yilmaz, Fatma; Koklu, Seyfettin // Rheumatology International;Apr2009, Vol. 29 Issue 6, p651 

    Anti-TNF-α agents are increasingly used in rheumatoid arthritis (RA) treatment and that is known to increase the risk of tuberculosis (TB) reactivation. Adenosine deaminase (ADA) levels are shown to increase to high levels in TB patients. Our aim is to investigate the serum ADA levels in RA...

  • Certolizumab Injection.  // AHFS Consumer Medication Information;Apr2018, p1 

    Certolizumab injection is used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: Crohn's disease (a condition in which the body attacks the lining of the...

  • La era dorada del tratamiento de la artritis reumatoide. Mercado, Ulises // Revista Medica del IMSS;mar/abr2014, Vol. 52 Issue 2, p126 

    Today, we enjoy the golden age of rheumatology. In the 1970s, the paradigm for treating rheumatoid arthritis consisted in a pyramid. In the decade of the 1980s, and shortly after began a revolution in the understanding and treatment of rheumatic diseases. Methotrexate and tumor necrosis...

  • Wonder Drugs May Treat Many Conditions. Dye, Dayna // Life Extension;Nov2008, Vol. 14 Issue 11, p23 

    The article offers information on the significance of tumor necrosis factor-alpha (TNF-alpha) in treating rheumatoid arthritis. It notes that the drugs which shown a protective effect in patients afflicted with autoimmune disease, contains inflixmab, entanercept, and adalimumab. Moreover, these...

  • Arana to begin Second Phase II Trial of Lead Compound ART621.  // Australasian Biotechnology;Sep2008, Vol. 18 Issue 3, p123 

    The article reports on the plan of Arana Therapeutics® to start the second phase II trial of the lead compound ART621 for the treatment of rheumatoid arthritis by the end of 2008. The class of drugs is used for the treatment of inflammatory diseases and works by blocking the action of tumour...

  • Does Anti-Tumor Necrosis Factor Therapy Increase the Risk of Surgical Site Infection (SSI) in Patients with Rheumatoid Arthritis?  // Clinical Infectious Diseases;6/1/2007, Vol. 44 Issue 11, pv 

    The article presents information about a study conducted by researcher A.A. den Broeder and colleagues to examine whether anti-tumor necrosis factor therapies increase the risk of surgical site infection (SSI) in patients with rheumatoid arthritis. Researchers analyzed the risk factors for SSI...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics